Combination of glycolysis inhibition with chemotherapy results in an antitumor immune response.
about
Energy disruptors: rising stars in anticancer therapy?Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma.Combinatorial strategies for the induction of immunogenic cell death.Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis.Immunogenic calreticulin exposure occurs through a phylogenetically conserved stress pathway involving the chemokine CXCL8.Tumor glycolysis as a target for cancer therapy: progress and prospects.The wonders of 2-deoxy-D-glucose.Multi-tasking of biosynthetic and energetic functions of glycolysis explained by supply and demand logic.How does metabolism affect cell death in cancer?Targeting cancer cell mitochondria as a therapeutic approach: recent updates.Hyperthermic intraperitoneal chemotherapy leads to an anticancer immune response via exposure of cell surface heat shock protein 90.2-Deoxyglucose induces cell cycle arrest and apoptosisin colorectal cancer cells independent of its glycolysis inhibition.GAPDH enhances the aggressiveness and the vascularization of non-Hodgkin's B lymphomas via NF-κB-dependent induction of HIF-1α.Role of AMP-activated protein kinase activators in antiproliferative multi-drug pituitary tumour therapies: effects of combined treatments with compounds affecting the mTOR-p70S6 kinase axis in cultured pituitary tumour cells.Glucose-6-phosphatase is a key metabolic regulator of glioblastoma invasion.Interplay between the intracellular energy sensor AMP-activated protein kinase (AMPK) and the estrogen receptor activities in regulating rat pituitary tumor cell (GH3) growth in vitro.Tumor cells and memory T cells converge at glycolysis: therapeutic implications.Promoting thiol expression increases the durability of antitumor T-cell functions.Consensus guidelines for the detection of immunogenic cell death.Targeting energy metabolism of cancer cells: Combined administration of NCL-240 and 2-DG.Regulation of Tumor Progression by Programmed Necrosis.
P2860
Q26771300-D82A3FE7-09DD-4E16-9FD5-F03B8E7F7576Q35273555-92E1AE17-91CF-497F-90A0-CA44C1017F55Q35535140-EF387AD3-2C3A-4E78-B95B-843A8AF46185Q36405508-35ADCFF1-8230-4BD7-8510-464D41C18A92Q37379408-54EAE633-2A3C-4BD2-9AD9-0EFD93FC602CQ38168262-5E89B93B-94B6-4804-9B40-8EB235E309C4Q38191881-CB5A1F4C-B53A-45C7-9FC5-68C92532A457Q38263318-E8DDD62B-CD19-4AF4-9E32-625A3BF5B79CQ38615890-4DA6CF20-2F9F-4897-8CCD-2DDCA68D3525Q38668524-812A6110-1D91-4147-AD82-A3BA492EBD57Q38888148-2472C1A2-DFF0-4F14-B630-4AD93330DF7BQ38902242-C3F4084B-DEEF-4D0E-879F-B881DD86DBD3Q38940618-868A4AE8-31FB-4378-A064-7133A484BF23Q38947158-4EF348EB-A463-448B-AB9F-03B4374D2147Q38977444-94AD5AC1-D512-4429-ABA3-8277E36141CCQ39155376-CD8761EF-B204-4FFB-A99E-6C678D0CD605Q39741801-5F8387C0-D07A-4983-AFF9-6CA8C06EC40AQ42549343-0A9862C3-05A1-4935-8980-CE184D29FE35Q42553556-FE982213-B3A9-46F9-BBE6-5DE4444A7AF8Q50428793-464643F3-036A-41FF-B284-F565AE9E459BQ52720171-8B7BF60F-C312-4901-8331-60898E265087
P2860
Combination of glycolysis inhibition with chemotherapy results in an antitumor immune response.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Combination of glycolysis inhi ...... an antitumor immune response.
@ast
Combination of glycolysis inhi ...... an antitumor immune response.
@en
type
label
Combination of glycolysis inhi ...... an antitumor immune response.
@ast
Combination of glycolysis inhi ...... an antitumor immune response.
@en
prefLabel
Combination of glycolysis inhi ...... an antitumor immune response.
@ast
Combination of glycolysis inhi ...... an antitumor immune response.
@en
P2093
P2860
P356
P1476
Combination of glycolysis inhi ...... n an antitumor immune response
@en
P2093
Aurore Cornille
Barbara Zunino
Jean-Ehrland Ricci
Johanna Chiche
Ludivine A Pradelli
Marie A Jacquin
Marie Bénéteau
Michel Carles
Ophélie Meynet
P2860
P304
20071-20076
P356
10.1073/PNAS.1206360109
P407
P577
2012-11-19T00:00:00Z